Urology Annals

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 9  |  Issue : 3  |  Page : 261--267

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study


Yasushi Tanuma1, Yoshinori Tanaka2, Ko Takeyama3, Tomoshi Okamoto4 
1 Department of Urology, Hokkaido Social Welfare Association Hakodate Hospital, Hakodate, Japan
2 Department of Urology, Hokkaido Prefectural Esashi Hospital, Esashi, Japan
3 Department of Urology, Hakodate National Hospital, Hakodate, Japan
4 Okamoto Urology Clinic, Hokkaido, Japan

Correspondence Address:
Yasushi Tanuma
Department of Urology, Hokkaido Social Welfare Association Hakodate Hospital, 4-6 Komaba-cho, Hakodate, Hokkaido 042-0935
Japan

Introduction: We evaluated the predictive factors which affect the efficacy of naftopidil 50 mg/day therapy and dose increase therapy to administration of 75 mg/day after an initial dose of 50 mg/day. Materials and Methods: A total of 92 patients with male lower urinary tract symptoms/benign prostatic hyperplasia were administrated naftopidil 50 mg/day for 4 weeks (50 mg therapy). At week 4, the patients were divided into an effective and an ineffective group (Group E and Group I, respectively). For further 4 weeks, the dosage of naftopidil was increased to 75 mg/day in all patients. At week 8, the patients of Group E and Group I were divided into an effective and an ineffective group (Group EE, Group EI, Group IE, and Group II, respectively). Results: Postvoid residual (PVR) urine volume at baseline was a predictive factor for efficacy of 50 mg therapy. In Group E, change in International Prostate Symptom Score storage symptoms subscore from baseline to week 4 was a predictive factor for efficacy of this dose increase therapy. In Group I, change in maximum flow rate from baseline to week 4 was a predictive factor for efficacy of this dose increase therapy. Conclusions: The short term of naftopidil 50 mg therapy was ineffective for the patients who had large PVR. The predictive factor of this dose increase therapy might be a dynamic variable in 50 mg/day of dose period, but not a baseline variable at the time of 75 mg/day dosage starts.


How to cite this article:
Tanuma Y, Tanaka Y, Takeyama K, Okamoto T. The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study.Urol Ann 2017;9:261-267


How to cite this URL:
Tanuma Y, Tanaka Y, Takeyama K, Okamoto T. The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study. Urol Ann [serial online] 2017 [cited 2020 Sep 20 ];9:261-267
Available from: http://www.urologyannals.com/article.asp?issn=0974-7796;year=2017;volume=9;issue=3;spage=261;epage=267;aulast=Tanuma;type=0